AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2021
Feb 12, 2021
31580_dirs_2021-02-12_56ee04e3-06c4-41cd-a340-aa2acc83d540.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2021-02-10
Reporting Person: Alenson Carman (Principal Accounting Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-02-10 | Restricted stock units | $ | A | 5922 | Acquired | Common stock (5922.0) | Direct | |
| 2021-02-10 | Stock option (right to buy) | $56.68 | A | 2961 | Acquired | 2031-02-10 | Common stock (2961.0) | Direct |
Footnotes
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments.
F3: This option was granted on February 10, 2021. The shares underlying this option vest as to 25% of the underlying shares on February 10, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.